Yung-Jue Bang

Yung-Jue Bang at Seoul National University led the TOGA phase III trial that established trastuzumab as the first targeted therapy approved for HER2-positive gastric cancer, fundamentally changing treatment for this molecular subgroup. His contributions to understanding HER2 biology and testing in gastric cancer have been foundational for the field. He has led or participated in numerous subsequent pivotal gastric cancer trials and has been a key figure in Asian and international gastric cancer research networks. His legacy includes defining the HER2-targeted treatment paradigm that opened the era of molecularly targeted therapy in gastric cancer.